HealthDay: Immunotherapy drug did not increase adverse surgery events
A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery.
HealthDay featured the research, recently published in JAMA Otolaryngology - Head & Neck Surgery, that evaluated outcomes during and after surgery when patients with head and neck cancer were given the immunotherapy drug pembrolizumab prior to surgery.
"What we found was that patients who received preoperative treatment with immunotherapy did not have an increase in morbidities around the time of surgery,” said Alice Tang, MD, first author on the study, assistant professor of clinical otolaryngology in UC’s College of Medicine, a UC Health physician and a University of Cincinnati Cancer Center member.
Featured photo at top of Alice Tang, MD, center, with patient. Photo provided by UC Health.
Related Stories
These teeny spiders are social media stars
August 28, 2026
The New York Times turned to a University of Cincinnati professor to explain the appeal of jumping spiders on social media.
An internal divide among unions on AI impacts the Wisconsin gubernatorial race
August 28, 2026
Anne Lofaso, a professor in the Donald P. Klekamp College of Law at UC, spoke with Wisconsin Public Radio, about the schism among unions over AI and whether it is a plus, a negative, or somewhere in between when looking at job creation.
On-site training in Speech & Hearing Clinic sets UC’s programs apart
August 27, 2026
At the University of Cincinnati’s Speech & Hearing Clinic, Doctor of Audiology and Speech-Language Pathology graduate students gain real-world experience while providing free speech and hearing services to the community.